Close Menu

NEW YORK – Genomics analysis firm ArcherDx has filed a regulatory document with the US Securities and Exchange Commission to go public with plans to raise up to $100 million.

The Boulder, Colorado-based company has not priced the offering or said how many shares it expects to offer in its Form S-1 filed on Friday. JP Morgan, Bank of America Securities, Stiffel, and Evercore ISI are listed as the proposed offering's underwriters. ArcherDx plans to list its stock on the Nasdaq under ticker symbol "RCHR".

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.